What is the efficacy of adalimumab in the treatment of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

Two placebo-controlled trials, CLASSIC I and II (CLinical assessment of Adalimumab Safety and efficacy Studied as Induction therapy in Crohn’s disease), showed that adalimumab was effective for both induction and maintenance of remission in patients who were previously naive to anti-TNF therapy. [26, 100]

The CHARM (Crohn’s trial of the fully Human antibody Adalimumab for Remission Maintenance) trial demonstrated the same effect in a mixed population of patients who were either naive to infliximab therapy or who had previously been on infliximab therapy. [101] In patients who had lost response to or become intolerant of infliximab, the GAIN (Gauging Adalimumab efficacy in Infliximab Nonresponders) trial results showed a benefit from adalimumab therapy induction with remission at 4 weeks. [102]

Furthermore, an open-label study conducted in France that assessed the long-term efficacy and safety of adalimumab maintenance therapy in this population showed that it was well tolerated and effective in maintaining clinical remission in patients who had Crohn disease with a lost response to or intolerance of infliximab. [26, 103, 104]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!